Long-term enoximone therapy in unstable chronic heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Unstable chronic heart failure (CHF) requires effective long-term management.
• Current therapies (digitalis, diuretics, vasodilators) may be insufficient for some CHF patients.

Purpose of the Study:

• To assess the long-term safety and efficacy of oral enoximone in patients with unstable chronic heart failure.
• To evaluate enoximone's impact on functional class, hemodynamics, and survival.

Main Methods:

• A study involving 32 patients with unstable chronic heart failure receiving oral enoximone (75-150 mg t.i.d.) for an average of 32 weeks.
• Assessment included NYHA functional class, hemodynamic measurements (cardiac index, pulmonary artery pressure), echocardiography (fractional shortening), and survival analysis.

Main Results:

• Significant improvements in cardiac index (18%) and pulmonary artery pressure (-34%) were observed.
• Echocardiographic fractional shortening increased significantly over 26 weeks.
• 40% 1-year survival rate; pump failure was the primary cause of death.
• No serious adverse events or significant proarrhythmic effects were reported.

Conclusions:

• Long-term oral enoximone therapy is safe for unstable chronic heart failure patients.
• Enoximone provides sustained clinical and functional benefits.
• Overall survival in this high-risk group was not significantly improved by enoximone.